184 related articles for article (PubMed ID: 30353046)
1. Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.
Walaszek K; Lower EE; Ziolkowski P; Weber GF
Br J Cancer; 2018 Nov; 119(10):1259-1266. PubMed ID: 30353046
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer risk in papilloma patients: Osteopontin splice variants indicate prognosis.
Ziółkowski P; Woźniak M; Mansour A; An Y; Weber GF
Breast Cancer Res; 2022 Sep; 24(1):64. PubMed ID: 36175970
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical significance of osteopontin in calcified breast tissue.
Huan JL; Xing L; Qin XJ; Gao ZG; Pan XF; Zhao ZD
Asian Pac J Cancer Prev; 2012; 13(10):5219-23. PubMed ID: 23244138
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis.
Hao C; Wang Z; Gu Y; Jiang WG; Cheng S
Biomed Res Int; 2016; 2016():7310694. PubMed ID: 27462610
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients.
Hahnel A; Wichmann H; Greither T; Kappler M; Würl P; Kotzsch M; Taubert H; Vordermark D; Bache M
BMC Cancer; 2012 Apr; 12():131. PubMed ID: 22471890
[TBL] [Abstract][Full Text] [Related]
6. Increased osteopontin expression is associated with progression from vulvar precancerous lesions to vulvar squamous cell carcinoma.
Wu Z; Shen Y; Gong K; Wu Z; Zhang T; Zhang X; Li S
Arch Gynecol Obstet; 2014 Mar; 289(3):637-44. PubMed ID: 23978873
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin-c is a selective marker of breast cancer.
Mirza M; Shaughnessy E; Hurley JK; Vanpatten KA; Pestano GA; He B; Weber GF
Int J Cancer; 2008 Feb; 122(4):889-97. PubMed ID: 17960616
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of Osteopontin splice variants in cancer.
An Y; Fnu G; Xie C; Weber GF
BMC Cancer; 2023 Apr; 23(1):373. PubMed ID: 37095438
[TBL] [Abstract][Full Text] [Related]
10. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.
Psyrri A; Kalogeras KT; Wirtz RM; Kouvatseas G; Karayannopoulou G; Goussia A; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Economopoulou P; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
J Transl Med; 2017 Feb; 15(1):30. PubMed ID: 28193231
[TBL] [Abstract][Full Text] [Related]
11. Nuclear osteopontin-c is a prognostic breast cancer marker.
Zduniak K; Ziolkowski P; Ahlin C; Agrawal A; Agrawal S; Blomqvist C; Fjällskog ML; Weber GF
Br J Cancer; 2015 Feb; 112(4):729-38. PubMed ID: 25625274
[TBL] [Abstract][Full Text] [Related]
12. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin expression in a group of lymph node negative breast cancer patients.
Tuck AB; O'Malley FP; Singhal H; Harris JF; Tonkin KS; Kerkvliet N; Saad Z; Doig GS; Chambers AF
Int J Cancer; 1998 Oct; 79(5):502-8. PubMed ID: 9761120
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin level and promoter polymorphism in patients with metastatic breast cancer.
Elbaiomy MA; Akl T; Elhelaly R; El-Beshbishi W; El Ghonemy MS; Elzehery R
Curr Oncol; 2020 Oct; 27(5):e444-e450. PubMed ID: 33173383
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin splice variants are differential predictors of breast cancer treatment responses.
Zduniak K; Agrawal A; Agrawal S; Hossain MM; Ziolkowski P; Weber GF
BMC Cancer; 2016 Jul; 16():441. PubMed ID: 27400751
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin knockdown inhibits αv,β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR pathway.
Zhang H; Guo M; Chen JH; Wang Z; Du XF; Liu PX; Li WH
Cell Physiol Biochem; 2014; 33(4):991-1002. PubMed ID: 24714122
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer.
Patani N; Jouhra F; Jiang W; Mokbel K
Anticancer Res; 2008; 28(6B):4105-10. PubMed ID: 19192668
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma.
Ferreira LB; Eloy C; Pestana A; Lyra J; Moura M; Prazeres H; Tavares C; Sobrinho-Simões M; Gimba E; Soares P
Eur J Endocrinol; 2016 Apr; 174(4):551-61. PubMed ID: 26811408
[TBL] [Abstract][Full Text] [Related]
19. [Expression of osteopontin splice variant and its clinical significance in gastric cancer].
Sun X; Wang L; Hou W; Li Y; Liu L; Zuo W; Yu J
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):427-30. PubMed ID: 26463145
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
